Collaboration at Its Core: Launching Spain’s First Fully Integrated Spatial Omics Platform

Why It Matters

The platform gives Spain a unique capability to study disease mechanisms in situ, speeding precision‑medicine research and strengthening the country’s biotech competitiveness.

Key Takeaways

• First fully integrated spatial omics platform in Spain
• Combines transcriptomics, proteomics, histopathology, microscopy, bioinformatics
• Offers end‑to‑end workflow from sample to analysis
• Supports cancer, neurodegeneration, cardiovascular, immune research
• Positions IRB Barcelona as European reference hub

Pulse Analysis

Spatial omics has moved from a niche technique to a cornerstone of modern biology, allowing scientists to retain the anatomical context of cells while profiling their molecular content. This contextual insight is especially valuable for heterogeneous diseases such as cancer, where tumor microenvironments dictate therapeutic response. By situating IRB Barcelona’s new platform at the intersection of transcriptomics, proteomics and high‑resolution imaging, the institute provides researchers with a single access point to generate multi‑modal datasets that were previously scattered across disparate facilities.

The integrated workflow eliminates the bottlenecks that often arise when moving samples between core services. Researchers can now submit a tissue block, receive coordinated preparation, multiplexed staining, and automated data pipelines that culminate in interactive spatial atlases. Such standardisation boosts reproducibility, shortens project timelines, and lowers the technical barrier for labs lacking in‑house expertise. Moreover, the platform’s bioinformatics core applies machine‑learning tools to fuse gene‑expression, protein‑distribution and histopathological layers, delivering comprehensive molecular maps ready for downstream hypothesis testing.

Beyond scientific merit, the platform positions Spain as a hub for spatial biology, attracting collaborations with pharmaceutical companies and international consortia focused on precision medicine. Access to this infrastructure accelerates biomarker discovery, informs patient stratification, and supports the development of spatially guided therapeutics. As the technology matures, IRB Barcelona’s model of collaborative, open‑access core facilities could become the template for other research ecosystems seeking to translate high‑dimensional spatial data into clinical impact.